Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Mar 28, 2020
Filed with the SEC on May 1, 2020 and accepted by EDGAR at May 1, 2020, 11:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-03-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-01-01 to 2020-03-28 | $6.23bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2020-01-01 to 2020-03-28 | $245.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-01-01 to 2020-03-28 | $1.55bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-01-01 to 2020-03-28 | $906.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-01-01 to 2020-03-28 | $126.0m | us-gaap:InterestExpense |
| Income tax | 3 months2020-01-01 to 2020-03-28 | $40.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-01-01 to 2020-03-28 | $788.0m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2020-01-01 to 2020-03-28 | $1.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-01-01 to 2020-03-28 | $1.99 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-01-01 to 2020-03-28 | 400,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2020-01-01 to 2020-03-28 | $356.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2020-01-01 to 2020-03-28 | $253.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2020-01-01 to 2020-03-28 | $76.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2020-01-01 to 2020-03-28 | $1.50bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-03-28 | $2.98bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-03-28 | $12.74bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-03-28 | $58.69bn | us-gaap:Assets |
| Current liabilities | At period end2020-03-28 | $5.50bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2020-03-28 | $19.23bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2020-03-28 | $738.0m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2020-03-28 | $28.56bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2020-03-28 | 394,951,104 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-20-000018. Last ingested by Listed: Nov 14, 2026, 12:05 ET. Listed shows no prices and gives no investment advice.